...offices. The round will remain open to raise additional funds to bring the company’s preclinical SLC13A5...

...Evotec will discover small molecule inhibitors against solute carrier family 13 sodium-dependent citrate transporter member 5 (SLC13A5) to treat metabolic diseases. Eternygen, which operates as...

...SLC13A5 could help treat obesity and type 2 diabetes. In mice fed a high-fat diet, Slc13a5...
...body mass and better hepatic insulin responsiveness than Slc13a5 expression. Next steps could include studying SLC13A5...